Erythropoietin Receptor Contributes to Melanoma Cell Survival in vivo

Erythropoietin (Epo) is widely used clinically to treat anemia associated with various clinical conditions including cancer. Data from several clinical trials suggest significant adverse effect of Epo treatment on cancer patient survival. However, controversy exists whether erythropoietin receptor (...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Suresh M., Zhang, Gao, Bastian, Boris C., Arcasoy, Murat O., Karande, Pankaj, Pushparajan, Anitha, Acs, Geza, Xu, Xiaowei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441831/
https://www.ncbi.nlm.nih.gov/pubmed/21860424
http://dx.doi.org/10.1038/onc.2011.366

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441831/
https://www.ncbi.nlm.nih.gov/pubmed/21860424
http://dx.doi.org/10.1038/onc.2011.366

Ejemplares similares